ARTERRA BIOSCIENCE SPA (ARBS.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:ARBS - IT0005386369 - Common Stock
3.08 EUR
+0.06 (+1.99%)
Taking everything into account, ARBS scores 4 out of 10 in our fundamental rating. ARBS was compared to 0 industry peers in the Unkown industry. ARBS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ARBS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ARBS was profitable.
In the past year ARBS had a positive cash flow from operations.
In the past 5 years ARBS has always been profitable.
In the past 5 years ARBS always reported a positive cash flow from operatings.
1.2 Ratios
The 3 year average ROIC (9.13%) for ARBS is below the current ROIC(13.11%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.59% | ||
| ROE | 16.33% | ||
| ROIC | 13.11% |
ROA(3y)9.93%
ROA(5y)10.02%
ROE(3y)11.74%
ROE(5y)12.1%
ROIC(3y)9.13%
ROIC(5y)9.66%
1.3 Margins
ARBS's Profit Margin has been stable in the last couple of years.
In the last couple of years the Operating Margin of ARBS has remained more or less at the same level.
In the last couple of years the Gross Margin of ARBS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 46.43% | ||
| PM (TTM) | 42.38% | ||
| GM | 63.6% |
OM growth 3Y0.28%
OM growth 5Y-1.05%
PM growth 3Y3.33%
PM growth 5Y0.25%
GM growth 3Y-2.51%
GM growth 5Y-0.98%
2. Health
2.1 Basic Checks
ARBS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for ARBS remains at a similar level compared to 1 year ago.
The number of shares outstanding for ARBS has been reduced compared to 5 years ago.
The debt/assets ratio for ARBS has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 7.28 indicates that ARBS is not in any danger for bankruptcy at the moment.
The Debt to FCF ratio of ARBS is 0.30, which is an excellent value as it means it would take ARBS, only 0.30 years of fcf income to pay off all of its debts.
ARBS has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Although ARBS does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.3 | ||
| Altman-Z | 7.28 |
ROIC/WACC1.43
WACC9.15%
2.3 Liquidity
ARBS has a Current Ratio of 7.40. This indicates that ARBS is financially healthy and has no problem in meeting its short term obligations.
ARBS has a Quick Ratio of 6.31. This indicates that ARBS is financially healthy and has no problem in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.4 | ||
| Quick Ratio | 6.31 |
3. Growth
3.1 Past
ARBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.48%, which is quite impressive.
Measured over the past years, ARBS shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.01% on average per year.
Looking at the last year, ARBS shows a quite strong growth in Revenue. The Revenue has grown by 13.44% in the last year.
Measured over the past years, ARBS shows a quite strong growth in Revenue. The Revenue has been growing by 9.02% on average per year.
EPS 1Y (TTM)37.48%
EPS 3Y8.02%
EPS 5Y10.01%
EPS Q2Q%109.79%
Revenue 1Y (TTM)13.44%
Revenue growth 3Y2.94%
Revenue growth 5Y9.02%
Sales Q2Q%14.28%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 10.27 indicates a reasonable valuation of ARBS.
Compared to an average S&P500 Price/Earnings ratio of 26.57, ARBS is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.27 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.78 | ||
| EV/EBITDA | 6.94 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.03
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.33%, ARBS is a good candidate for dividend investing.
Compared to an average S&P500 Dividend Yield of 1.88, ARBS pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.33% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
44.46% of the earnings are spent on dividend by ARBS. This is a bit on the high side, but may be sustainable.
DP44.46%
EPS Next 2YN/A
EPS Next 3YN/A
BIT:ARBS (12/22/2025, 7:00:00 PM)
3.08
+0.06 (+1.99%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)
Earnings (Next)
Inst Owners0.16%
Inst Owner ChangeN/A
Ins Owners46.87%
Ins Owner ChangeN/A
Market Cap20.51M
Revenue(TTM)4.49M
Net Income(TTM)1.90M
Analysts82.86
Price Target3.88 (25.97%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.33% |
Yearly Dividend0.11
Dividend Growth(5Y)N/A
DP44.46%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.56%
PT rev (3m)5.56%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.27 | ||
| Fwd PE | N/A | ||
| P/S | 4.56 | ||
| P/FCF | 19.78 | ||
| P/OCF | 10.79 | ||
| P/B | 1.76 | ||
| P/tB | 1.76 | ||
| EV/EBITDA | 6.94 |
EPS(TTM)0.3
EY9.74%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.16
FCFY5.06%
OCF(TTM)0.29
OCFY9.27%
SpS0.67
BVpS1.75
TBVpS1.75
PEG (NY)N/A
PEG (5Y)1.03
Graham Number3.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.59% | ||
| ROE | 16.33% | ||
| ROCE | 16.27% | ||
| ROIC | 13.11% | ||
| ROICexc | 17.92% | ||
| ROICexgc | 17.98% | ||
| OM | 46.43% | ||
| PM (TTM) | 42.38% | ||
| GM | 63.6% | ||
| FCFM | 23.07% |
ROA(3y)9.93%
ROA(5y)10.02%
ROE(3y)11.74%
ROE(5y)12.1%
ROIC(3y)9.13%
ROIC(5y)9.66%
ROICexc(3y)15.47%
ROICexc(5y)17.58%
ROICexgc(3y)15.82%
ROICexgc(5y)18.81%
ROCE(3y)11.33%
ROCE(5y)12.02%
ROICexgc growth 3Y-16.84%
ROICexgc growth 5Y-17%
ROICexc growth 3Y-14.48%
ROICexc growth 5Y-12.8%
OM growth 3Y0.28%
OM growth 5Y-1.05%
PM growth 3Y3.33%
PM growth 5Y0.25%
GM growth 3Y-2.51%
GM growth 5Y-0.98%
F-Score6
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.3 | ||
| Debt/EBITDA | 0.11 | ||
| Cap/Depr | 269.44% | ||
| Cap/Sales | 19.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 78.96% | ||
| Profit Quality | 54.44% | ||
| Current Ratio | 7.4 | ||
| Quick Ratio | 6.31 | ||
| Altman-Z | 7.28 |
F-Score6
WACC9.15%
ROIC/WACC1.43
Cap/Depr(3y)76.68%
Cap/Depr(5y)90.12%
Cap/Sales(3y)7.07%
Cap/Sales(5y)10.14%
Profit Quality(3y)69.73%
Profit Quality(5y)57.78%
High Growth Momentum
Growth
EPS 1Y (TTM)37.48%
EPS 3Y8.02%
EPS 5Y10.01%
EPS Q2Q%109.79%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.44%
Revenue growth 3Y2.94%
Revenue growth 5Y9.02%
Sales Q2Q%14.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y62.77%
EBIT growth 3Y3.23%
EBIT growth 5Y7.88%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-57.65%
FCF growth 3Y-20.26%
FCF growth 5Y25.42%
OCF growth 1Y3.72%
OCF growth 3Y-8.67%
OCF growth 5Y-9.31%
ARTERRA BIOSCIENCE SPA / ARBS.MI FAQ
Can you provide the ChartMill fundamental rating for ARTERRA BIOSCIENCE SPA?
ChartMill assigns a fundamental rating of 4 / 10 to ARBS.MI.
What is the valuation status for ARBS stock?
ChartMill assigns a valuation rating of 1 / 10 to ARTERRA BIOSCIENCE SPA (ARBS.MI). This can be considered as Overvalued.
What is the profitability of ARBS stock?
ARTERRA BIOSCIENCE SPA (ARBS.MI) has a profitability rating of 3 / 10.
What is the valuation of ARTERRA BIOSCIENCE SPA based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ARTERRA BIOSCIENCE SPA (ARBS.MI) is 10.27 and the Price/Book (PB) ratio is 1.76.
Is the dividend of ARTERRA BIOSCIENCE SPA sustainable?
The dividend rating of ARTERRA BIOSCIENCE SPA (ARBS.MI) is 4 / 10 and the dividend payout ratio is 44.46%.